Stock Screener App

Frei -

Installieren

Drug Manufacturers - General

24.39

0.53% -0.13

after-market

Handel nachbörslich: 24.43 0.04 +0.16%

Pfizer Inc (PFE)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt PFE? Forum Prognose Aktiensplit Dividendenhistorie

Pfizer Inc Aktie (PFE) Neueste Nachrichten

Why Moderna Might Be a One-Hit Wonder - The Motley Fool

AstraZeneca joins Pfizer in most-favored nation pricing program - TechTarget

Advanced Ovarian Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer - Barchart.com

GSK Fights Pfizer's Bid To Nix COVID-19 Vaccine Patents - Law360

Pfizer CEO Says Vaccine Approvals Are Harder to Get Right Now - Bloomberg.com

Pfizer CEO Reportedly Says US Pharmaceutical Industry Should Collaborate With Chinese Counterparts - MarketScreener

Pfizer touts Tukysa in front-line breast cancer after Phase III victory - Yahoo Finance

Pfizer touts new Phase III win for Tukysa in front-line breast cancer - The Pharma Letter

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga

Pfizer (PFE) CEO Advocates for Collaboration with China's Pharma Industry - GuruFocus

Pfizer (PFE) CEO Highlights China's Rapid Drug Development - GuruFocus

Pfizer CEO touts China's 'dramatic speed' in biopharma, calls for U.S. collaboration - Seeking Alpha

Day 7 of Loss Streak for Pfizer Stock with -10% Return (vs. -2.6% YTD) [10/14/2025] - Trefis

Pfizer: CN Biopharma Sector Shows Astonishing Growth; US Drug Industry Must Collaborate with CN - AASTOCKS.com

Pfizer CEO says US pharma industry needs to collaborate with China - Reuters

Lobbying Update: $30,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative

Pfizer (PFE) Faces Continued Losses Despite Bullish Analyst Rati - GuruFocus

Is Pfizer’s Latest Drug Pricing Deal a Turning Point for 2025 Valuation? - simplywall.st

Pfizer CEO Urges US-China Collaboration In Pharma; Stock Drops For 7th Day As Traders Hold For Dividend Payout - Stocktwits

Pfizer (PFE) Receives a Buy from BMO Capital - The Globe and Mail

Pfizer Seeks Expanded Use Approval For Breast Cancer Drug - Benzinga

Pfizer's (PFE) Tukysa Achieves Key Milestone in Breast Cancer Tr - GuruFocus

Pfizer (PFE) Receives a Hold from Bernstein - The Globe and Mail

Pfizer posts late-stage trial win for cancer drug (PFE:NYSE) - Seeking Alpha

Pfizer (PFE) Reports Positive Results from Key Breast Cancer Tri - GuruFocus

Pfizer Says Tukysa Combination as First-Line Maintenance Meets Main Goal in Breast Cancer Trial - MarketScreener

Tukysa combination significantly improves progression-free survival as first-line maintenance in HER2+ metastatic breast cancer in HER2CLIMB-05 trial - MarketScreener

Pfizer’s breast cancer drug shows promise in first-line treatment - Investing.com

Pfizer’s breast cancer drug shows promise in first-line treatment By Investing.com - Investing.com India

Day 6 of Loss Streak for Pfizer Stock with -9.6% Return (vs. -1.8% YTD) [10/13/2025] - Trefis

Pfizer’s (PFE) Pipeline and Dividend Yield Make it a Compelling Income Stock - Yahoo Finance

Trump's AstraZeneca Deal Echoes Pfizer Pact. Big Pharma's Political Headaches Are Easing. - Barron's

AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve - The Globe and Mail

Pfizer Reaches Agreement with U.S. Government to Lower Drug Costs - Contract Pharma

Lawsuits Claim Pfizer Failed to Warn of Brain Tumor Risk From Birth Control Shot - Truthout

Trump Secures Major Win as AstraZeneca Joins Pfizer in Lowering US Drug Prices - Medical Daily

Global markets live: Blackstone, Pfizer, Tesla, Stellantis, AstraZeneca… - MarketScreener

Pfizer stock rises as BMO Capital reiterates Outperform rating - Investing.com

How Pfizer Inc. (PFE) Affects Rotational Strategy Timing - news.stocktradersdaily.com

Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know - Yahoo Finance

IP Group shares fly on back of Metsera & Pfizer news - BusinessCloud

Verdence Capital Advisors LLC Increases Stake in Pfizer Inc. $PFE - MarketBeat

Pfizer To Highlight Advancements In Respiratory Health And Infectious Disease Research At IDWeek 2025 - TradingView

Griffin Asset Management Inc. Grows Holdings in Pfizer Inc. $PFE - MarketBeat

Pfizer to present infectious disease data at IDWeek 2025 - Investing.com

Concurrent Investment Advisors LLC Purchases 20,663 Shares of Pfizer Inc. $PFE - MarketBeat

Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025 - Business Wire

Vanguard Personalized Indexing Management LLC Grows Position in Pfizer Inc. $PFE - MarketBeat

Pfizer, Inc. (PFE) Stock Analysis: Exploring the 16% Upside Potential and Robust Dividend Yield - DirectorsTalk Interviews

Estrogen Blockers Market Is Booming Worldwide 2025-2032 | Pfizer Inc., Novartis AG, AstraZeneca PLC - openPR.com

IP Group in line for future royalties from Pfizer’s drug deal - Proactive Investors

FY2025 EPS Estimates for Pfizer Lowered by Cantor Fitzgerald - MarketBeat

Is Pfizer (NYSE:PFE) Using Too Much Debt? - Yahoo Finance

Cwm LLC Raises Stake in Pfizer Inc. $PFE - MarketBeat

Sippican Capital Advisors Has $2.25 Million Stock Holdings in Pfizer Inc. $PFE - MarketBeat

Means Investment CO. Inc. Sells 22,379 Shares of Pfizer Inc. $PFE - MarketBeat

Callan Family Office LLC Purchases 48,269 Shares of Pfizer Inc. $PFE - MarketBeat

Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (October 2025) - 24/7 Wall St.

Pfizer (PFE) Faces Challenges Amid Drug Pricing Push - GuruFocus

LaRuby May and team of attorneys file suit against Pfizer, claim negligence in premature release of sickle cell drug therapy - AFRO American Newspapers

Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com

Pfizer's Deal on Drug Prices Gets Closer to the Right Idea - Advisor Perspectives

Guggenheim Keeps Their Buy Rating on Pfizer (PFE) - The Globe and Mail

Pfizer Inc. $PFE Shares Bought by Fifth Third Wealth Advisors LLC - MarketBeat

Drucker Wealth 3.0 LLC Sells 15,443 Shares of Pfizer Inc. $PFE - MarketBeat

Aberdeen Group plc Increases Position in Pfizer Inc. $PFE - MarketBeat

Pfizer Inc. | Pharmaceuticals, Vaccines & Company History | Britannica Money - Britannica

Pfizer (NYSE:PFE) Trading Down 1.7%What's Next? - MarketBeat

Pfizer (PFE) Target Price Lowered by Morgan Stanley | PFE Stock News - GuruFocus

Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly - WHTC

GILD

$118.30

0.15%

SNY

$48.96

0.53%

AMGN

$297.32

1.18%

NVO

$56.72

0.11%

MRK

$84.11

0.70%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters